Indication
Celiac Disease
20 clinical trials
25 products
1 drug
Clinical trial
A Phase 1 Placebo-Controlled, Double-Blind Crossover Study to Assess Psychological Effects of MDMA When Administered to Healthy VolunteersStatus: Completed, Estimated PCD: 2022-08-05
Product
PlaceboProduct
MTX-101Product
VTP-1000Clinical trial
A Phase 1, First in Human, Randomized, Placebo-controlled Trial With a Controlled Gluten Challenge to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VTP-1000 in Adults With Celiac DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-08-01
Product
KAN-101Clinical trial
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)Status: Completed, Estimated PCD: 2021-10-08
Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients With Non-Responsive Celiac Disease as an Adjunct to a Gluten-free DietStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Product
PRV-015Clinical trial
A Multicentre, SAD, and MAD Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV Treatment of CALY-002 in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic EsophagitisStatus: Completed, Estimated PCD: 2024-04-02
Product
CALY-002Product
TAK-062Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free DietStatus: Active (not recruiting), Estimated PCD: 2025-05-06
Product
GSK3915393Clinical trial
A Randomized, Placebo Controlled, Double Blind, Single and Repeat Dose Escalation Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and Open Label Assessment of Coadministration of GSK3915393 With Grapefruit Juice and Itraconazole on the Pharmacokinetics of GSK3915393Status: Completed, Estimated PCD: 2021-06-29
Product
ItraconazoleClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac DiseaseStatus: Completed, Estimated PCD: 2008-06-01
Product
CCX282-BProduct
AMG 714Product
TPM502Clinical trial
A Double-blind, Randomized, Placebo-controlled, Phase 2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamic (PD) Effects of Two Infusions of Escalating Doses of TPM502 in Adults Diagnosed With Celiac DiseaseStatus: Recruiting, Estimated PCD: 2024-05-30
Product
LatiglutenaseClinical trial
Prospective, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Type 1 Diabetes Patients With Celiac Disease While Undergoing Periodic Gluten ExposureStatus: Terminated, Estimated PCD: 2022-12-19
Clinical trial
Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet While Undergoing Periodic Gluten ExposureStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
DONQ52Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study)Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Effect of Acetaminophen Versus Ibuprofen in Treating Recurrent Apthous Ulcers in Pediatric Celiac Disease: A Randomized Pilot StudyStatus: Not yet recruiting, Estimated PCD: 2024-09-01
Product
AcetaminophenProduct
IbuprofenClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free DietStatus: Recruiting, Estimated PCD: 2025-10-30
Product
TAK-101Clinical trial
Genetic and Biological Background and Follow-up of Different Phenotypes of Coeliac DiseaseStatus: Recruiting, Estimated PCD: 2027-12-31
Product
Genetic predispositionClinical trial
A Phase 1B Open-label/Phase 2 Double-blind Placebo- Controlled Study for Pharmacodynamic (PD) Activity, Pharmacokinetics (PK), Safety, and Tolerability of KAN-101 In Patients With Celiac Disease (CeD)Status: Recruiting, Estimated PCD: 2024-12-31
Product
Cohort 1Product
Cohort 2Product
Group 2Product
Group 3Product
Group 4Clinical trial
A Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac DiseaseStatus: Recruiting, Estimated PCD: 2025-03-01
Drug
VarlilumabClinical trial
Effect of the Endopeptidase AN-PEP on Gluten Exposure in Real Life in Celiac Disease Patients Treated With a Long-term Gluten-free Diet. Exploratory, Interventional, Prospective, Controlled and Double Blind StudyStatus: Completed, Estimated PCD: 2022-07-30
Product
Prolyl EndopeptidaseClinical trial
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in RemissionStatus: Recruiting, Estimated PCD: 2025-08-01
Product
Ritlecitinib